STSA - Satsuma Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.92
-1.19 (-7.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close15.11
Open15.26
Bid10.50 x 800
Ask13.94 x 1000
Day's Range13.66 - 15.60
52 Week Range8.61 - 19.90
Volume82,552
Avg. Volume80,961
Market Cap241.87M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.20
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • GlobeNewswire

    Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins,.

  • GlobeNewswire

    Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results

    Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of migraine.

  • Barrons.com

    Primo Water, Bellus Health and Other 13D Filings

    Legion Partners Asset Management revealed ownership of 3,567,946 shares of the purified-water retailer, equal to 9.1% of the publicly traded stock. On Sept. 17, Legion Partners issued a press release in conjunction with a public letter to shareholders conveying its displeasure with what Legion Partners believes to be the board’s insufficient oversight that has led to the stock’s recent underperformance. Legion Partners feels that a complete “board refresh” is needed to improve corporate independence and governance, and to eliminate long-serving directors whose complacency has “failed to hold management accountable” for poor operational performance.

  • Largest Insider Trades of the Week
    GuruFocus.com

    Largest Insider Trades of the Week

    Insiders pile on shares of Kraft Heinz, shed Overstock Continue reading...

  • PR Newswire

    Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering

    SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing ...

  • Cloudflare IPO Prices Above Range, Raises $525 Million
    Investor's Business Daily

    Cloudflare IPO Prices Above Range, Raises $525 Million

    Internet services company Cloudflare was set to begin trading Friday, after raising $525 million with an initial public offering that priced Thursday. Cloudflare offered 35 million shares.

  • PR Newswire

    Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing ...

  • Benzinga

    Satsuma Pharma IPO: What You Need To Know

    South San Francisco-based Satsuma Pharmaceuticals, Inc. has filed for an IPO of 5 million shares of its common stock. The company said in the filing that some of its existing investors affiliated with some of its directors have expressed interest in buying about $25 million in shares. Founded in June 2016, Satsuma is a clinical-stage biopharma company developing a novel therapeutic product for the acute treatment of migraines.

  • PR Newswire

    Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Satsuma. In addition, Satsuma expects to grant the underwriters for the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.